2. Korea Centers for Disease Control and Prevention. Epidemiology and management of vaccine preventable disease. 5th ed. Cheongju: Korea Centers for Disease Control and Prevention; 2017. p 187-202 (Korean).
3. Paddock CD, Sanden GN, Cherry JD, Gal AA, Langston C, Tatti KM, et al. Pathology and pathogenesis of fatal Bordetella pertussis infection in infants. Clin Infect Dis 2008;47:328-338. PMID:
18558873
4. Sealey KL, Belcher T, Preston A. Bordetella pertussis epidemiology and evolution in the light of pertussis resurgence. Infect Genet Evol 2016;40:136-143.
5. Ebell MH, Marchello C, Callahan M. Clinical diagnosis of Bordetella pertussis infection: a systematic review. J Am Board Fam Med 2017;30:308-319.
6. Wendelboe AM, Njamkepo E, Bourillon A, Floret DD, Gaudelus J, Gerber M, et al. Transmission of bordetella pertussis to young infants. Pediatr Infect Dis J 2007;26:293-299.
8. Yeung KH, Duclos P, Nelson EA, Hutubessy RC. An update of the global burden of pertussis in children younger than 5 years: a modelling study. Lancet Infect Dis 2017;17:974-980.
9. Bamberger ES, Srugo I. What is new in pertussis? Eur J Pediatr 2008;167:133-139.
12. von König CH, Halperin S, Riffelmann M, Guiso N. Pertussis of adults and infants. Lancet Infect Dis 2002;2:744-750.
13. Korea Centers for Disease Control and Prevention. 2017 Infectious diseases surveillance yearbook. Cheongju: Korea Centers for Disease Control and Prevention; 2018. p 21 (Korean).
14. Korea Centers for Disease Control and Prevention. 2012 Infectious diseases surveillance yearbook. Cheongju: Korea Centers for Disease Control and Prevention; 2013. p 21 (Korean).
15. Korea Centers for Disease Control and Prevention. 2015 Infectious diseases surveillance yearbook. Cheongju: Korea Centers for Disease Control and Prevention; 2016. p 21 (Korean).
19. Bouchez V, Guiso N. Bordetella pertussis, B. parapertussis, vaccines and cycles of whooping cough. Pathog Dis 2015;73:ftv055.
21. Korea Centers for Disease Control and Prevention. Guideline for vaccine-preventable diseases. Cheongju: Korea Centers for Disease Control and Prevention; 2021. p 79 (Korean).
22. Yang Y, Land KC. Age-period-cohort analysis: new models, methods, and empirical applications. 1st ed. Boca Raton: CRC Press; 2013. p 1, 107.
27. Oh CM, Jung KW, Won YJ, Shin A, Kong HJ, Lee JS. Age-period-cohort analysis of thyroid cancer incidence in Korea. Cancer Res Treat 2015;47:362-369.
28. Suzuki E. Time changes, so do people. Soc Sci Med 2012;75:452-456.
29. Choe YJ, Lee YH, Cho SI. Increasing mumps incidence rates among children and adolescents in the Republic of Korea: age-period-cohort analysis. Int J Infect Dis 2017;57:92-97.
30. Yang Y, Schulhofer‐Wohl S, Fu W. The intrinsic estimator for age-period-cohort analysis: what it is and how to use it. Am J Sociol 2008;113:1697-1736.
31. O’Brien RM. Cohort variations in suicide rates among families of nations: an analysis of cohorts born from 1875 through 1985. Int J Comp Sociol 2006;47:5-33.
33. Yasui Y, Mitsui T, Nishimura T, Uchida K, Inokuchi M, Mori M, et al. School-age children and adolescents suspected of having been to be infected with pertussis in Japan. Vaccine 2018;36:2910-2915.
35. Mooi FR, Van Der Maas NA, De Melker HE. Pertussis resurgence: waning immunity and pathogen adaptation - two sides of the same coin. Epidemiol Infect 2014;142:685-694.
37. Aguas R, Gonçalves G, Gomes MG. Pertussis: increasing disease as a consequence of reducing transmission. Lancet Infect Dis 2006;6:112-117.
39. Cherry JD. Pertussis in the preantibiotic and prevaccine era, with emphasis on adult pertussis. Clin Infect Dis 1999;28:S107-S111.
40. George RH. Passive immunity to pertussis in newborns. Pediatr Infect Dis J 1990;9:374.
41. Van Rie A, Wendelboe AM, Englund JA. Role of maternal pertussis antibodies in infants. Pediatr Infect Dis J 2005;24:S62-S65.
43. Barug D, Pronk I, van Houten MA, Versteegh FGA, Knol MJ, van de Kassteele J, et al. Maternal pertussis vaccination and its effects on the immune response of infants aged up to 12 months in the Netherlands: an open-label, parallel, randomised controlled trial. Lancet Infect Dis 2019;19:392-401.